This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
convalescent plasma | 663 |
extracellular vesicles | 576 |
summary conclusion | 561 |
flow cytometry | 170 |
plasma therapy | 151 |
derived evs | 146 |
electron microscopy | 146 |
cell lines | 145 |
nanoparticle tracking | 138 |
tracking analysis | 134 |
breast cancer | 130 |
whole blood | 125 |
western blot | 111 |
endothelial cells | 110 |
prostate cancer | 104 |
human plasma | 102 |
cancer cells | 100 |
stem cells | 98 |
plasma samples | 95 |
bone marrow | 94 |
amino acid | 94 |
stem cell | 92 |
mass spectrometry | 91 |
acute respiratory | 87 |
cancer patients | 83 |
multiple myeloma | 83 |
usa introduction | 81 |
plasma exchange | 81 |
extracellular vesicle | 81 |
exclusion chromatography | 79 |
transmission electron | 77 |
plasma proteins | 77 |
ng ml | 76 |
plasma protein | 73 |
plasma transfusion | 73 |
derived exosomes | 72 |
lung cancer | 72 |
recipient cells | 70 |
derived extracellular | 69 |
respiratory syndrome | 68 |
amino acids | 67 |
cancer cell | 67 |
molecular weight | 65 |
mesenchymal stem | 64 |
size exclusion | 64 |
clinical trials | 63 |
severe acute | 63 |
western blotting | 62 |
cell culture | 61 |
cell line | 60 |
blood samples | 60 |
critically ill | 58 |
immune response | 57 |
ill patients | 57 |
blood cells | 57 |
ev isolation | 57 |
differentially expressed | 57 |
cell types | 56 |
source plasma | 56 |
lyophilized plasma | 56 |
mg kg | 55 |
factor viii | 54 |
liquid biopsy | 54 |
red blood | 54 |
plasma donation | 53 |
small rna | 52 |
healthy controls | 52 |
platelet activation | 51 |
risk factors | 49 |
size distribution | 49 |
blood donation | 49 |
density gradient | 48 |
coronavirus disease | 47 |
conditioned media | 47 |
platelet aggregation | 47 |
differential ultracentrifugation | 47 |
small extracellular | 47 |
antibody titers | 46 |
nucleic acids | 46 |
gene expression | 46 |
plasma products | 46 |
antibody titer | 45 |
isolated evs | 44 |
evs derived | 44 |
severe covid | 44 |
apc resistance | 44 |
ev markers | 44 |
tumour cells | 44 |
ev cargo | 43 |
immune system | 43 |
platelet count | 43 |
surface markers | 43 |
blood products | 42 |
intercellular communication | 42 |
viral inactivation | 42 |
enveloped viruses | 41 |
ev release | 41 |
plasma cell | 41 |
colorectal cancer | 41 |
neutralizing antibodies | 41 |
side effects | 40 |
frozen plasma | 40 |
significantly higher | 40 |
dried plasma | 40 |
endothelial cell | 39 |
low molecular | 39 |
evs isolated | 39 |
ebola virus | 39 |
protein content | 39 |
mg dl | 38 |
conditioned medium | 38 |
isolation methods | 38 |
coagulation factors | 37 |
smooth muscle | 37 |
differential centrifugation | 37 |
evs released | 37 |
free dna | 36 |
cord uid | 36 |
patients treated | 36 |
doc id | 36 |
plasma treatment | 36 |
clinical trial | 35 |
blood plasma | 35 |
syndrome coronavirus | 34 |
neutralizing antibody | 34 |
control group | 34 |
proteomic analysis | 34 |
caprylic acid | 34 |
oxidative stress | 34 |
myocardial infarction | 34 |
isolated using | 34 |
plasma evs | 34 |
culture media | 34 |
cells treated | 34 |
ev subpopulations | 34 |
eligibility criteria | 33 |
important role | 33 |
activated protein | 33 |
plasma exudation | 33 |
immune cells | 32 |
risk factor | 32 |
tissue factor | 32 |
wound healing | 32 |
healthy subjects | 32 |
epithelial cells | 32 |
mortality rate | 32 |
significantly increased | 31 |
cell communication | 31 |
intensive care | 31 |
protein cargo | 31 |
united states | 31 |
fresh frozen | 31 |
plasma cells | 31 |
willebrand factor | 31 |
target cells | 31 |
small evs | 31 |
respiratory distress | 30 |
present study | 30 |
performed using | 30 |
thrombocytopenic purpura | 30 |
cell surface | 30 |
healthy volunteers | 30 |
early detection | 29 |
data suggest | 29 |
first time | 29 |
ev production | 29 |
peripheral blood | 29 |
protein markers | 29 |
growth factor | 29 |
protein binding | 29 |
therapeutic plasma | 29 |
tumour microenvironment | 29 |
plasma amino | 28 |
protein expression | 28 |
may also | 28 |
analysis revealed | 28 |
total protein | 28 |
exosomes derived | 28 |
renal failure | 28 |
plasma donors | 27 |
thrombotic thrombocytopenic | 27 |
adverse events | 27 |
another study | 27 |
infectious diseases | 27 |
circulating evs | 27 |
hemorrhagic shock | 27 |
host cells | 27 |
patients compared | 27 |
normal range | 27 |
particle size | 27 |
venous thrombosis | 27 |
von willebrand | 26 |
mouse model | 26 |
significant differences | 26 |
surface marker | 26 |
nucleic acid | 26 |
informed consent | 26 |
rna sequencing | 26 |
distress syndrome | 26 |
significantly reduced | 25 |
median age | 25 |
platelet concentrates | 25 |
cd cd | 25 |
inflammatory response | 25 |
human umbilical | 25 |
quality control | 25 |
culture medium | 25 |
clotting time | 25 |
novel coronavirus | 25 |
viral reduction | 25 |
extracellular matrix | 25 |
analysis showed | 25 |
stromal cells | 25 |
commercially available | 25 |
human blood | 25 |
cell death | 24 |
cell proliferation | 24 |
results indicate | 24 |
results suggest | 24 |
plasminogen activator | 24 |
growth factors | 24 |
poorly understood | 24 |
tumour growth | 24 |
organ failure | 24 |
thrombus formation | 24 |
lung injury | 24 |
ev numbers | 24 |
plasma membrane | 24 |
plasma fractionation | 23 |
membrane vesicles | 23 |
widely used | 23 |
blood loss | 23 |
dna damage | 23 |
mesenchymal stromal | 23 |
public health | 23 |
ms ms | 23 |
blood pressure | 23 |
viral load | 23 |
plasma levels | 23 |
virus infection | 23 |
hav ig | 23 |
ex vivo | 23 |
cell type | 23 |
threatening covid | 23 |
umbilical cord | 23 |
particles ml | 23 |
exosomes isolated | 23 |
infectious agents | 23 |
significant difference | 23 |
recent studies | 22 |
poor prognosis | 22 |
derived ev | 22 |
ev protein | 22 |
body fluids | 22 |
dependent manner | 22 |
ev preparations | 22 |
single ev | 22 |
septic shock | 22 |
cerebrospinal fluid | 22 |
evs may | 22 |
outer membrane | 22 |
blood cell | 22 |
thrombin generation | 22 |
drug administration | 21 |
measured using | 21 |
ev proteins | 21 |
degradation products | 21 |
increased levels | 21 |
healthy individuals | 21 |
significantly lower | 21 |
inflammatory cytokines | 21 |
analysed using | 21 |
blot analysis | 21 |
ev populations | 21 |
antibody levels | 21 |
hospitalized patients | 21 |
tumour progression | 21 |
wide range | 21 |
viral safety | 21 |
data show | 21 |
circulating tumor | 21 |
soluble fibrin | 21 |
randomized controlled | 21 |
previous studies | 21 |
early diagnosis | 21 |
clinical studies | 21 |
nervous system | 21 |
ev surface | 21 |
vein thrombosis | 21 |
pg ml | 21 |
ovarian cancer | 21 |
evs showed | 21 |
associated proteins | 20 |
drug resistance | 20 |
room temperature | 20 |
determine whether | 20 |
molecular mechanisms | 20 |
exosome secretion | 20 |
clotting factors | 20 |
cancer detection | 20 |
small rnas | 20 |
coagulation factor | 20 |
therapeutic potential | 20 |
cellular uptake | 20 |
factor vii | 20 |
plasma collection | 20 |
different types | 20 |
pathogen reduction | 20 |
spanish flu | 20 |
clinical symptoms | 20 |
nach der | 20 |
type diabetes | 20 |
blood components | 20 |
healthy donors | 20 |
pulse sensing | 20 |
clinical applications | 20 |
exchange chromatography | 20 |
plasma proteome | 19 |
acute phase | 19 |
significant increase | 19 |
virus inactivation | 19 |
umbilical vein | 19 |
platelet counts | 19 |
may provide | 19 |
east respiratory | 19 |
one patient | 19 |
high levels | 19 |
serum samples | 19 |
clinical use | 19 |
high risk | 19 |
two different | 19 |
large evs | 19 |
cd evs | 19 |
infected cells | 19 |
animal models | 19 |
resistive pulse | 19 |
brain injury | 19 |
revised eligibility | 19 |
ev secretion | 19 |
physical activity | 19 |
middle east | 19 |
plasma sample | 19 |
wild type | 19 |
bleeding complications | 19 |
pathway analysis | 19 |
potential biomarkers | 19 |
cell derived | 19 |
msc evs | 18 |
differential expression | 18 |
systematic review | 18 |
treated patients | 18 |
airway mucosa | 18 |
plasma pools | 18 |
statistically significant | 18 |
sample size | 18 |
may contribute | 18 |
confocal microscopy | 18 |
mechanical ventilation | 18 |
muscle cells | 18 |
tumour cell | 18 |
antibody responses | 18 |
cell lung | 18 |
ev biogenesis | 18 |
total evs | 18 |
light chain | 18 |
blood donors | 18 |
prothrombin time | 18 |
antibody response | 18 |
disease progression | 18 |
diabetes mellitus | 18 |
pulmonary embolism | 18 |
pathogen inactivation | 18 |
different ev | 18 |
ev size | 18 |
purified evs | 18 |
cancer progression | 18 |
uv light | 18 |
venous thromboembolism | 18 |
culture conditions | 18 |
findings suggest | 17 |
mirna expression | 17 |
controlled trial | 17 |
ev uptake | 17 |
coronavirus infection | 17 |
ultraviolet light | 17 |
markers cd | 17 |
vascular permeability | 17 |
deep vein | 17 |
case series | 17 |
tangential flow | 17 |
blood flow | 17 |
new york | 17 |
vein endothelial | 17 |
signalling pathways | 17 |
type ii | 17 |
platelet function | 17 |
iu ml | 17 |
increased expression | 17 |
evs secreted | 17 |
data demonstrate | 17 |
family members | 17 |
flow filtration | 17 |
flow cytometer | 17 |
cell evs | 17 |
clinically normal | 17 |
thrombotic events | 17 |
protein levels | 17 |
cell activation | 17 |
regenerative medicine | 17 |
size range | 17 |
blood group | 17 |
key role | 17 |
medical center | 17 |
ev samples | 17 |
commonly used | 17 |
expression levels | 17 |
signalling pathway | 17 |
cell function | 17 |
epithelial cell | 16 |
biomarker discovery | 16 |
evs using | 16 |
assessed using | 16 |
previously shown | 16 |
der regel | 16 |
reference interval | 16 |
passive immunization | 16 |
may lead | 16 |
evs containing | 16 |
drug delivery | 16 |
triple negative | 16 |
potential therapeutic | 16 |
brain barrier | 16 |
coronary artery | 16 |
future studies | 16 |
crc patients | 16 |
higher levels | 16 |
virus disease | 16 |
immune responses | 16 |
feline plasma | 16 |
exosome isolation | 16 |
free plasma | 16 |
coagulation parameters | 16 |
cells using | 16 |
three different | 16 |
times higher | 16 |
replacement therapy | 16 |
light scattering | 16 |
traumatic brain | 16 |
tumor dna | 16 |
total rna | 16 |
plasma infusion | 16 |
small cell | 16 |
respiratory failure | 16 |
ischemic stroke | 16 |
preliminary data | 16 |
patients received | 16 |
ig titers | 16 |
pilot study | 16 |
monoclonal antibody | 16 |
proteomic profiling | 16 |
human igg | 16 |
gradient ultracentrifugation | 16 |
patients undergoing | 16 |
cytokine storm | 16 |
infectious disease | 16 |
circulating extracellular | 16 |
currently available | 16 |
adverse effects | 15 |
dendritic cells | 15 |
clinical signs | 15 |
day mortality | 15 |
solvent detergent | 15 |
year old | 15 |
evs produced | 15 |
plasma exudate | 15 |
previously described | 15 |
ig products | 15 |
increased risk | 15 |
blood safety | 15 |
central nervous | 15 |
serious adverse | 15 |
ev research | 15 |
cd exo | 15 |
plasma collected | 15 |
viral infections | 15 |
oral anticoagulation | 15 |
thromboplastin time | 15 |
bacterial evs | 15 |
ev treatment | 15 |
treated cells | 15 |
bleeding time | 15 |
case report | 15 |
national institutes | 15 |
negative breast | 15 |
ev concentration | 15 |
inflammatory mediators | 15 |
blood coagulation | 15 |
multiple organ | 15 |
mg ml | 15 |
machine learning | 15 |
characterized using | 15 |
plasma derived | 15 |
similar results | 15 |
data analysis | 15 |
patients showed | 15 |
blood transfusion | 15 |
ev quantification | 15 |
elevated levels | 15 |
early stage | 15 |
results demonstrate | 15 |
dependent enhancement | 15 |
studies will | 15 |
poor plasma | 15 |
thrombin inhibitors | 15 |
type i | 15 |
small ev | 15 |
rich plasma | 15 |
exosomal mir | 15 |
cell viability | 15 |
potential role | 15 |
urine samples | 15 |
point mutation | 15 |
bone metastasis | 15 |
highly sensitive | 15 |
different cell | 15 |
expression analysis | 15 |
immune cell | 15 |
anticoagulant therapy | 14 |
years old | 14 |
wt mice | 14 |
using differential | 14 |
red cell | 14 |
thrombin time | 14 |
determined using | 14 |
mirna cargo | 14 |
world health | 14 |
cancer diagnosis | 14 |
monoclonal gammopathy | 14 |
labelled evs | 14 |
abundant proteins | 14 |
network structure | 14 |
cells may | 14 |
retrospective study | 14 |
specific markers | 14 |
thermo fisher | 14 |
low ph | 14 |
significantly decreased | 14 |
using flow | 14 |
hiv infection | 14 |
quantified using | 14 |
acute lung | 14 |
will provide | 14 |
predictive value | 14 |
induced platelet | 14 |
liquid biopsies | 14 |
biological activity | 14 |
dnase turbo | 14 |
fold change | 14 |
pancreatic cancer | 14 |
studies suggest | 14 |
national institute | 14 |
blood collection | 14 |
guinea pig | 14 |
mitochondrial dysfunction | 14 |
antithrombin iii | 14 |
ev detection | 14 |
pooled plasma | 14 |
clinical data | 14 |
surface protein | 14 |
sars patients | 14 |
monoclonal antibodies | 14 |
ev yield | 14 |
marrow plasmacytosis | 14 |
results showed | 14 |
und die | 14 |
gel electrophoresis | 14 |
plasma units | 14 |
donor centre | 14 |
results show | 14 |
studies showed | 14 |
dynamic range | 14 |
hydrostatic pressure | 14 |
adipose tissue | 14 |
liquid chromatography | 14 |
different isolation | 14 |
immunodeficiency virus | 14 |
cell cultures | 14 |
pulmonary edema | 14 |
study revealed | 14 |
analysis using | 14 |
symptom onset | 14 |
plasma using | 14 |
controlled trials | 14 |
better understanding | 14 |
airway lumen | 13 |
well known | 13 |
may serve | 13 |
specific antibodies | 13 |
rna cargo | 13 |
liver disease | 13 |
generation sequencing | 13 |
patients receiving | 13 |
patients without | 13 |
bei der | 13 |
least one | 13 |
respiratory infections | 13 |
thrombotic complications | 13 |
normal plasma | 13 |
cell cycle | 13 |
thrombin receptor | 13 |
weight heparin | 13 |
fisher scientific | 13 |
recent years | 13 |
cell migration | 13 |
basal cells | 13 |
reduced mortality | 13 |
inhibitory effect | 13 |
organ dysfunction | 13 |
intravenous immunoglobulin | 13 |
body weight | 13 |
significant reduction | 13 |
essential amino | 13 |
fluorescently labelled | 13 |
pa activity | 13 |
protease inhibitors | 13 |
study aimed | 13 |
human brain | 13 |
molecular cargo | 13 |
taken together | 13 |
blood supply | 13 |
clinical features | 13 |
health organization | 13 |
rights reserved | 13 |
dynamic light | 13 |
using convalescent | 13 |
coagulation system | 13 |
fibrinolytic system | 13 |
medical research | 13 |
control samples | 13 |
ev released | 13 |
lupus anticoagulant | 13 |
fold higher | 13 |
plasma recipients | 13 |
national cancer | 13 |
chain proteinuria | 13 |
fractionation process | 13 |
fibrin monomer | 13 |
within hours | 13 |
acute myocardial | 13 |
samples collected | 13 |
sevs isolated | 13 |
expressed proteins | 13 |
der spender | 13 |
exosomal rna | 13 |
study group | 13 |
investigate whether | 13 |
showed significant | 13 |
using nanoparticle | 13 |
heat treatment | 13 |
reactive protein | 13 |
highly purified | 13 |
human immunodeficiency | 13 |
study will | 13 |
exosomal mirna | 12 |
expression patterns | 12 |
ethanol fractionation | 12 |
gene ontology | 12 |
engineered evs | 12 |
activator inhibitor | 12 |
ev concentrations | 12 |
fold increase | 12 |
data suggests | 12 |
clinical improvement | 12 |
care unit | 12 |
lymph nodes | 12 |
nk cells | 12 |
pluripotent stem | 12 |
bronchial asthma | 12 |
plasma concentrations | 12 |
proteome analysis | 12 |
high purity | 12 |
drug discovery | 12 |
therapeutic effect | 12 |
centre staff | 12 |
vesicles introduction | 12 |
convalescent sera | 12 |
vascular smooth | 12 |
exosome markers | 12 |
luminal entry | 12 |
el paso | 12 |
cognitive impairment | 12 |
magnetic beads | 12 |
therapeutic efficacy | 12 |
chain reaction | 12 |
may play | 12 |
good manufacturing | 12 |
also used | 12 |
convalescent serum | 12 |
per ml | 12 |
pd patients | 12 |
deficient plasma | 12 |
hepatocellular carcinoma | 12 |
per cell | 12 |
swarm detection | 12 |
bovine serum | 12 |
protein biomarkers | 12 |
largely unknown | 12 |
factor xii | 12 |
signal transduction | 12 |
neurological disorders | 12 |
normal human | 12 |
tissue culture | 12 |
spike antibody | 12 |
basement membrane | 12 |
platelet adhesion | 12 |
cohort study | 12 |
study showed | 12 |
patient plasma | 12 |
zeta potential | 12 |
two groups | 12 |
mast cells | 12 |
total ev | 12 |
heart failure | 12 |
factor ix | 12 |
cell therapy | 12 |
great potential | 12 |
platelet surface | 12 |
parental cells | 12 |
using two | 12 |
exosomal markers | 12 |
specific ev | 12 |
crucial role | 12 |
clot formation | 12 |
standard deviation | 12 |
expression level | 12 |
disease control | 12 |
therapeutic strategies | 12 |
leading cause | 12 |
laboratory tests | 12 |
affected cats | 12 |
scanning electron | 12 |
heparin therapy | 12 |
neurodegenerative diseases | 12 |
gradient centrifugation | 12 |
large scale | 12 |
viral rna | 12 |
fluorescence microscopy | 12 |
immune globulin | 12 |
therapeutic applications | 12 |
imaging flow | 11 |
functional assays | 11 |
coagulation tests | 11 |
preliminary results | 11 |
level digraph | 11 |
nile virus | 11 |
characterize evs | 11 |
plasma donor | 11 |
novel biomarkers | 11 |
atypical hus | 11 |
plasma ev | 11 |
also observed | 11 |
membrane protein | 11 |
cd expression | 11 |
vascular leakage | 11 |
epidermal growth | 11 |
sars coronavirus | 11 |
durch die | 11 |
therapeutic strategy | 11 |
may occur | 11 |
three days | 11 |
diabetic patients | 11 |
lavage fluid | 11 |
expression profiles | 11 |
derived sevs | 11 |
complement activation | 11 |
pivotal role | 11 |
clotting assays | 11 |
cam evs | 11 |
mitochondrial dna | 11 |
uremic syndrome | 11 |
acceptor cells | 11 |
thrombin inhibitor | 11 |
patients suffering | 11 |
data collection | 11 |
high dose | 11 |
platelet reactivity | 11 |
circulating cell | 11 |
time points | 11 |
cell carcinoma | 11 |
bacterial cells | 11 |
intravenous administration | 11 |
serum levels | 11 |
und der | 11 |
lipid bilayer | 11 |
ethics committee | 11 |
macrophage activation | 11 |
vivo studies | 11 |
raman spectroscopy | 11 |
midwest city | 11 |
will use | 11 |
vascular endothelial | 11 |
ad patients | 11 |
us fda | 11 |
western blots | 11 |
ev analysis | 11 |
low dose | 11 |
brain tissue | 11 |
also significantly | 11 |
per year | 11 |
may cause | 11 |
blood product | 11 |
crispr cas | 11 |
prothrombin fragment | 11 |
necrosis factor | 11 |
lung disease | 11 |
partial thromboplastin | 11 |
reference materials | 11 |
polymerase chain | 11 |
hong kong | 11 |
detection limit | 11 |
high throughput | 11 |
cd ev | 11 |
animal model | 11 |
activated platelets | 11 |
viii concentrate | 11 |
within days | 11 |
plasma may | 11 |
severe influenza | 11 |
coagulation activation | 11 |
infectious peritonitis | 11 |
lung diseases | 11 |
biological fluids | 11 |
cell membrane | 11 |
endoplasmic reticulum | 11 |
donor selection | 11 |
feline infectious | 11 |
circulating ev | 11 |
thrombolytic therapy | 11 |
high sensitivity | 11 |
der erythrozyten | 11 |
using different | 11 |
blood donor | 11 |
will allow | 11 |
lymph node | 11 |
evs compared | 11 |
plasma dna | 11 |
creative commons | 11 |
renal function | 11 |
clinical application | 11 |
compassionate use | 11 |
red cross | 11 |
expression profile | 11 |
misev guidelines | 11 |
normal cells | 11 |
cancer institute | 11 |
yon willebrand | 11 |
manufacturing processes | 11 |
innate immune | 11 |
protein spots | 11 |
potential biomarker | 11 |
high molecular | 11 |
related diseases | 11 |
mayo clinic | 11 |
also showed | 11 |
using size | 11 |
exosome release | 11 |
asthmatic airways | 11 |
nm ss | 11 |
associated protein | 11 |
validation studies | 11 |
cells showed | 11 |
viral infection | 10 |
significantly improved | 10 |
pore size | 10 |
patient samples | 10 |
thromboembolic complications | 10 |
convalescent blood | 10 |
evs contain | 10 |
based therapies | 10 |
bovine milk | 10 |
control subjects | 10 |
significantly elevated | 10 |
invasive biomarkers | 10 |
based method | 10 |
component analysis | 10 |
factor xiii | 10 |
detergent treatment | 10 |
mortality rates | 10 |
fully understood | 10 |
delivery systems | 10 |
leiden mutation | 10 |
free protein | 10 |
general population | 10 |
oxidized ldl | 10 |
disease patients | 10 |
canadian blood | 10 |
gbm cells | 10 |
next generation | 10 |
readily available | 10 |
cells release | 10 |
four patients | 10 |
oral anticoagulant | 10 |
feline multiple | 10 |
continuous infusion | 10 |
ev characterization | 10 |
cell lysates | 10 |
kg bw | 10 |
two patients | 10 |
auf die | 10 |
clinical course | 10 |
data indicate | 10 |
cell free | 10 |
novel therapeutic | 10 |
liver failure | 10 |
human serum | 10 |
manufacturing process | 10 |
barrier function | 10 |
behaviour change | 10 |
knowledge users | 10 |
plasma product | 10 |
bronchoalveolar lavage | 10 |
evs also | 10 |
different concentrations | 10 |
murine macrophages | 10 |
rna species | 10 |
physiological conditions | 10 |
ev collection | 10 |
type specific | 10 |
rna expression | 10 |
central role | 10 |
cells introduction | 10 |
human disease | 10 |
hours post | 10 |
ev mirna | 10 |
west nile | 10 |
small molecules | 10 |
induced pluripotent | 10 |
bioactive molecules | 10 |
cardiac events | 10 |
cell adhesion | 10 |
cartilage regeneration | 10 |
airway mucosal | 10 |
influenza pneumonia | 10 |
major depressive | 10 |
metastatic niche | 10 |
randomized clinical | 10 |
alkaline phosphatase | 10 |
pathological conditions | 10 |
igg preparations | 10 |
high expression | 10 |
treated plasma | 10 |
derived small | 10 |
specific mirnas | 10 |
disease biomarkers | 10 |
results obtained | 10 |
abo blood | 10 |
occlusive disease | 10 |
final concentration | 10 |
dry heat | 10 |
pal antigen | 10 |
cells expressing | 10 |
kidney disease | 10 |
therapeutic approach | 10 |
using ultracentrifugation | 10 |
different methods | 10 |
platelet products | 10 |
milk evs | 10 |
coding rnas | 10 |
plasma triacylglycerol | 10 |
circulating micrornas | 10 |
proteins may | 10 |
research council | 10 |
depressive disorder | 10 |
isolation method | 10 |
dnase i | 10 |
analysis methods | 10 |
therapeutic use | 10 |
thawed plasma | 10 |
ion exchange | 10 |
one case | 10 |
small size | 10 |
tissue damage | 10 |
five patients | 10 |
well suited | 10 |
specific biomarkers | 10 |
cardiovascular disease | 10 |
activation markers | 10 |
clinical practice | 10 |
convalescent whole | 10 |
sensitive strains | 9 |
factor receptor | 9 |
cardiovascular risk | 9 |
individual evs | 9 |
sera option | 9 |
japan introduction | 9 |
related acute | 9 |
transfused patients | 9 |
tf expression | 9 |
expressed mirnas | 9 |
sequencing data | 9 |
apc sensitivity | 9 |
seminal plasma | 9 |
lytic lesions | 9 |
clinical outcomes | 9 |
studies using | 9 |
expanded access | 9 |
novel biomarker | 9 |
antibody therapy | 9 |
may represent | 9 |
cell interactions | 9 |
human cells | 9 |
molecular markers | 9 |
current methods | 9 |
increased blood | 9 |
patients develop | 9 |
successfully used | 9 |
immune plasma | 9 |
disease severity | 9 |
carcinoma cells | 9 |
human monocytes | 9 |
cell morphology | 9 |
donor screening | 9 |
previously reported | 9 |
tandem mass | 9 |
preliminary report | 9 |
venous blood | 9 |
blood vessel | 9 |
analysis identified | 9 |
molecular changes | 9 |
state university | 9 |
molecular mechanism | 9 |
culture supernatant | 9 |
positive evs | 9 |
cell growth | 9 |
sulfur mustard | 9 |
acid precipitation | 9 |
novel antiviral | 9 |
fractionated products | 9 |
surface expression | 9 |
serum albumin | 9 |
severe bleeding | 9 |
cytokine production | 9 |
bacterial species | 9 |
peer review | 9 |
spinal cord | 9 |
successful treatment | 9 |
brain tissues | 9 |
oa chondrocytes | 9 |
protein concentrations | 9 |
epithelial lining | 9 |
neuronal cells | 9 |
vor der | 9 |
national university | 9 |
viral diseases | 9 |
seq data | 9 |
reactive oxygen | 9 |
postoperative day | 9 |
abundance proteins | 9 |
time course | 9 |
library preparation | 9 |
circulatory overload | 9 |
study included | 9 |
free nucleic | 9 |
risk markers | 9 |
clinical study | 9 |
evs resulted | 9 |
uk introduction | 9 |
viral shedding | 9 |
tof ms | 9 |
high quality | 9 |
fibrinogen levels | 9 |
com ccm | 9 |
will help | 9 |
cancer evs | 9 |
including exosomes | 9 |
von der | 9 |
single particle | 9 |
cancer therapy | 9 |
trauma patients | 9 |
passive immunity | 9 |
using anti | 9 |
plasma derivatives | 9 |
challenging due | 9 |
sev content | 9 |
better understand | 9 |
red cells | 9 |
functional studies | 9 |
apheresis plasma | 9 |
data showed | 9 |
factor xa | 9 |
diagnostic criteria | 9 |
protein composition | 9 |
blood type | 9 |
plasma sevs | 9 |
proteins identified | 9 |
spike protein | 9 |
proteins involved | 9 |
liver transplantation | 9 |
evs obtained | 9 |
thp cells | 9 |
specific evs | 9 |
first step | 9 |
cell populations | 9 |
increased plasma | 9 |
prospective study | 9 |
significantly different | 9 |
swine model | 9 |
containing covid | 9 |
proteomics analysis | 9 |
reperfusion injury | 9 |
protein products | 9 |
chagas disease | 9 |
exposed patients | 9 |
supplemental digital | 9 |
ev mirnas | 9 |
biological processes | 9 |
digital content | 9 |
gold standard | 9 |
viral loads | 9 |
skeletal muscle | 9 |
diarrheal hus | 9 |
systemic circulation | 9 |
flow cytometric | 9 |
patients developed | 9 |
binding protein | 9 |
cs sevs | 9 |
prothrombin fragments | 9 |
two weeks | 9 |
blood derivatives | 9 |
significant changes | 9 |
bacterial infections | 9 |
human lung | 9 |
treat covid | 9 |
beneficial effects | 9 |
los angeles | 9 |
soluble proteins | 9 |
relatively high | 9 |
evs play | 9 |
blood banking | 9 |
progenitor cell | 9 |
may affect | 9 |
negative control | 9 |
domains framework | 9 |
photochemical treatment | 9 |
airway absorption | 9 |
membrane proteins | 9 |
linked immunosorbent | 9 |
seven days | 9 |
der blutspende | 9 |
newly developed | 9 |
escherichia coli | 9 |
different sources | 9 |
vivo model | 9 |
gewinnung von | 9 |
old man | 9 |
chronic inflammation | 9 |
nsclc patients | 9 |
reference intervals | 9 |
various types | 9 |
ill covid | 9 |
data obtained | 9 |
naturally occurring | 9 |
theoretical domains | 9 |
alphav beta | 9 |
culture supernatants | 9 |
proinflammatory cytokines | 9 |
urinary extracellular | 9 |
clinical efficacy | 9 |
bulk plasma | 9 |
iodixanol density | 9 |
dedicated viral | 9 |
cs control | 9 |
viral replication | 9 |
effective treatment | 9 |
intranasal administration | 9 |
raman spectra | 9 |
developing countries | 9 |
fxii deficiency | 9 |
last years | 9 |
surface proteins | 9 |
overall survival | 9 |
urinary evs | 9 |
correlated well | 9 |
associated markers | 9 |
methylene blue | 9 |
recent study | 9 |
quantify evs | 9 |
clinically relevant | 9 |
copyright holder | 9 |
derived vesicles | 9 |
major role | 9 |
target cell | 9 |
autoimmune diseases | 9 |
single cell | 9 |
data may | 8 |
blood services | 8 |
dbh gene | 8 |
metastatic potential | 8 |
high incidence | 8 |
androgen receptor | 8 |
newly born | 8 |
cardiovascular diseases | 8 |
study provides | 8 |
liver cirrhosis | 8 |
protein ratio | 8 |
proteomic technologies | 8 |
crc cells | 8 |
therapeutic range | 8 |
cervical cancer | 8 |
new therapeutic | 8 |
hek cells | 8 |
long term | 8 |
case reports | 8 |
hyperimmune immunoglobulin | 8 |
mrna expression | 8 |
arterial thrombosis | 8 |
high concentrations | 8 |
current study | 8 |
calcium concentration | 8 |
therapeutic target | 8 |
phenotypic changes | 8 |
sev marker | 8 |
protein amount | 8 |
functional activity | 8 |
single molecule | 8 |
remains unknown | 8 |
ev loading | 8 |
human nasal | 8 |
invasive biomarker | 8 |
msc therapy | 8 |
obtained using | 8 |
therapeutic agents | 8 |
protein profile | 8 |
also found | 8 |
vast majority | 8 |
study using | 8 |
squamous cell | 8 |
renal disease | 8 |
passive immunotherapy | 8 |
cancer development | 8 |
primary tumour | 8 |
mucosal surface | 8 |
national blood | 8 |
clinical samples | 8 |
specific activity | 8 |
ev particles | 8 |
nitric oxide | 8 |
also demonstrated | 8 |
cord blood | 8 |
evs enriched | 8 |
may influence | 8 |
sulphate precipitation | 8 |
free medium | 8 |
proteomic profile | 8 |
total cholesterol | 8 |
sample processing | 8 |
donor cells | 8 |
ev biomarkers | 8 |
particle concentration | 8 |
body mass | 8 |
arachidonic acid | 8 |
passive antibody | 8 |
also reduced | 8 |
clinical outcome | 8 |
rna virus | 8 |
marrow aspirates | 8 |
ultracentrifugation method | 8 |
patients transfused | 8 |
cancer risk | 8 |
vivo experiments | 8 |
culture systems | 8 |
protein profiles | 8 |
density lipoprotein | 8 |
immunosorbent assay | 8 |
highly abundant | 8 |
produce evs | 8 |
two hours | 8 |
affinity chromatography | 8 |
therapeutic options | 8 |
mdd subjects | 8 |
patients recovered | 8 |
manufacturing practices | 8 |
antiviral drugs | 8 |
biologically active | 8 |
bleeding tendency | 8 |
clinical characteristics | 8 |
amniotic fluid | 8 |
recovered covid | 8 |
tube formation | 8 |
photochemical inactivation | 8 |
significant improvement | 8 |
esterase inhibitor | 8 |
highly expressed | 8 |
pfu ml | 8 |
reverse transcriptase | 8 |
may reflect | 8 |
induced apoptosis | 8 |
sodium citrate | 8 |
critical role | 8 |
terumo bct | 8 |
may prove | 8 |
chronic bronchitis | 8 |
control evs | 8 |
multiple sclerosis | 8 |
cancer stem | 8 |
mit der | 8 |
marker expression | 8 |
cvd risk | 8 |
tunable resistive | 8 |
circulating tumour | 8 |
als patients | 8 |
differential gene | 8 |
sm exposed | 8 |
diastolic bp | 8 |
wnt signalling | 8 |
positively charged | 8 |
significantly upregulated | 8 |
individual donations | 8 |
ev associated | 8 |
modern plasma | 8 |
rna transfer | 8 |
hirudin antibodies | 8 |
log pfu | 8 |
capillary leakage | 8 |
human urine | 8 |
protease inhibitor | 8 |
lateral sclerosis | 8 |
severely ill | 8 |
specific proteins | 8 |
exosome biogenesis | 8 |
flow fractionation | 8 |
cytometry analysis | 8 |
gene therapy | 8 |
written informed | 8 |
liver enzymes | 8 |
plasma extracellular | 8 |
lower mortality | 8 |
cd patients | 8 |
using nta | 8 |
study demonstrates | 8 |
hcv rna | 8 |
recently demonstrated | 8 |
cancer introduction | 8 |
fibrinolytic activity | 8 |
neurological signs | 8 |
nonenveloped viruses | 8 |
glioma cells | 8 |
containing evs | 8 |
metastatic breast | 8 |
induced aggregation | 8 |
signaling pathways | 8 |
tg ml | 8 |
characterized according | 8 |
prp tse | 8 |
total tau | 8 |
identified using | 8 |
patients introduction | 8 |
induced oxidative | 8 |
stromal cell | 8 |
electron microscope | 8 |
evs isolation | 8 |
high level | 8 |
acid concentrations | 8 |
myeloma patients | 8 |
acute liver | 8 |
ev marker | 8 |
plasma donations | 8 |
plasma use | 8 |
using evs | 8 |
ammonium sulphate | 8 |
amyotrophic lateral | 8 |
distinct populations | 8 |
based methods | 8 |
novel method | 8 |
clinical settings | 8 |
protein concentration | 8 |
stably expressing | 8 |
damage control | 8 |
vitro studies | 8 |
network analysis | 8 |
myc amplified | 8 |
university hospital | 8 |
vesicles released | 8 |
bleeding episodes | 8 |
hemostatic parameters | 8 |
pci mrna | 8 |
large amounts | 8 |
transfusion transmission | 8 |
knowledge translation | 8 |
sp i | 8 |
analysis indicated | 8 |
primary human | 8 |
recombinant hirudin | 8 |
cancer biomarkers | 8 |
potential donors | 8 |
von blut | 8 |
auch die | 8 |
ev subtypes | 8 |
mean diameter | 8 |
com scientificreports | 8 |
airway epithelium | 8 |
cells via | 8 |
artery disease | 8 |
will likely | 8 |
vitro study | 8 |
higher anti | 8 |
normal values | 8 |
ms analysis | 8 |
pregnant women | 8 |
epithelial barrier | 8 |
patient year | 8 |
digraph analysis | 8 |
medical university | 8 |
thromboembolic events | 8 |
ev fraction | 8 |
human subjects | 8 |
safety indicators | 8 |
ascorbic acid | 8 |
nmol i | 8 |
early safety | 8 |
tumor necrosis | 8 |
positively correlated | 8 |
spanish influenza | 8 |
hc ii | 8 |
plasma leakage | 8 |
acid ph | 8 |
may result | 7 |
cellular communication | 7 |
clotting assay | 7 |
muscle cell | 7 |
elevated anti | 7 |
within minutes | 7 |
convalescent covid | 7 |
atypical plasma | 7 |
acid treatment | 7 |
blood transfusions | 7 |
liquid plasma | 7 |
clot lysis | 7 |
sizeexclusion chromatography | 7 |
principal component | 7 |
mirna content | 7 |
adhesion molecules | 7 |
hemostatic system | 7 |
rag ko | 7 |
protein kinase | 7 |
several proteins | 7 |
ev derived | 7 |
rescue therapy | 7 |
protein contaminants | 7 |
control study | 7 |
amongst others | 7 |
cancer circulating | 7 |
clotting times | 7 |
university school | 7 |
actin fs | 7 |
laboratory findings | 7 |
clp mice | 7 |
statistical significance | 7 |
werden kann | 7 |
mouse models | 7 |
using elisa | 7 |
activated coagulation | 7 |
donor plasma | 7 |
reduced ev | 7 |
donor deferral | 7 |
immobilized heparin | 7 |
dmem supplemented | 7 |
increasing evidence | 7 |
cell tumors | 7 |
apoptotic bodies | 7 |
inhibitor patients | 7 |
york city | 7 |
functional effects | 7 |
based ev | 7 |
time period | 7 |
safety profile | 7 |
johns hopkins | 7 |
snake venom | 7 |
bcc proliferation | 7 |
model viruses | 7 |
human platelet | 7 |
quality assurance | 7 |
associated mirnas | 7 |
skin necrosis | 7 |
platelet factor | 7 |
anticoagulant effect | 7 |
airway epithelial | 7 |
human diseases | 7 |
well understood | 7 |
der spende | 7 |
ethanol supernatant | 7 |
experiments will | 7 |
cleaving protease | 7 |
treatment reduced | 7 |
via evs | 7 |
inflammatory effects | 7 |
author funder | 7 |
culture system | 7 |
born neurons | 7 |
filter system | 7 |
significantly altered | 7 |
gla domain | 7 |
eukaryotic cells | 7 |
dass die | 7 |
binding domain | 7 |
pc gr | 7 |
fluorescence intensity | 7 |
minimally invasive | 7 |
rpe cells | 7 |
us food | 7 |
based assays | 7 |
among patients | 7 |
transfection reagent | 7 |
discriminant analysis | 7 |
gp ib | 7 |
pepsin digestion | 7 |
detect evs | 7 |
canada introduction | 7 |
gastric cancer | 7 |
prognostic marker | 7 |
healthy women | 7 |
serial centrifugation | 7 |
healthy control | 7 |
delivery system | 7 |
present work | 7 |
serum mir | 7 |
granted medrxiv | 7 |
neurodegenerative disease | 7 |
notch signaling | 7 |
different subpopulations | 7 |
dermal fibroblasts | 7 |
circulating levels | 7 |
least days | 7 |
igg products | 7 |
studies demonstrated | 7 |
pig trachea | 7 |
closure time | 7 |
showed significantly | 7 |
biological samples | 7 |
sevs group | 7 |
surface antigen | 7 |
disease detection | 7 |
findings indicate | 7 |
years ago | 7 |
following treatment | 7 |
surface area | 7 |
ev field | 7 |
veterinary medicine | 7 |
correlation coefficient | 7 |
atomic force | 7 |
protein components | 7 |
high density | 7 |
clotting tests | 7 |
will enable | 7 |
standard curve | 7 |
ev rna | 7 |
chronic obstructive | 7 |
patient groups | 7 |
parental cell | 7 |
significant decrease | 7 |
test samples | 7 |
individual outcomes | 7 |
blood donations | 7 |
carotid artery | 7 |
heart rate | 7 |
asthmatic sputa | 7 |
mechanisms involved | 7 |
concentration range | 7 |
sequential ultracentrifugation | 7 |
results revealed | 7 |
regression model | 7 |
cells also | 7 |
possible mechanisms | 7 |
may therefore | 7 |
und nach | 7 |
blut und | 7 |
haematopoietic stem | 7 |
direct sequencing | 7 |
microfluidic resistive | 7 |
ad mice | 7 |
significantly downregulated | 7 |
receptor binding | 7 |
study also | 7 |
vehicle control | 7 |
previously showed | 7 |
supplementary table | 7 |
induced evs | 7 |
activating peptide | 7 |
epithelial damage | 7 |
transgene expression | 7 |
membrane dyes | 7 |
ev isolates | 7 |
results demonstrated | 7 |
based assay | 7 |
cd positive | 7 |
ist eine | 7 |
two covid | 7 |
guinea pigs | 7 |
genomic alterations | 7 |
received convalescent | 7 |
via extracellular | 7 |
improved survival | 7 |
cognitive function | 7 |
days post | 7 |
diagnostic test | 7 |
log reduction | 7 |
acute myeloid | 7 |
found elevated | 7 |
based therapy | 7 |
hit type | 7 |
wird durch | 7 |
research team | 7 |
collagen production | 7 |
platelet rich | 7 |
therapeutic effects | 7 |
recovered patients | 7 |
rna delivery | 7 |
gap closure | 7 |
mehr als | 7 |
icu admission | 7 |
will need | 7 |
prothrombin complex | 7 |
myeloid leukaemia | 7 |
healthcare workers | 7 |
isolate evs | 7 |
angina pectoris | 7 |
chromogenic assay | 7 |
sta aptt | 7 |
trend towards | 7 |
nm nanofiltration | 7 |
severe disease | 7 |
transmembrane protein | 7 |
time point | 7 |
plasma administration | 7 |
ev content | 7 |
even though | 7 |
ev purification | 7 |
four hours | 7 |
reporter system | 7 |
health care | 7 |
viral validation | 7 |
based liquid | 7 |
intravenous injection | 7 |
nach den | 7 |
patients diagnosed | 7 |
purification methods | 7 |
macsplex exosome | 7 |
many different | 7 |
copy number | 7 |
cell motility | 7 |
bioreactor system | 7 |
fatty acids | 7 |
using riboflavin | 7 |
fibrinogen concentration | 7 |
mirna profiling | 7 |
host immune | 7 |
exosome treatment | 7 |
cargo release | 7 |
different culture | 7 |
der transfusion | 7 |
resistant strains | 7 |
fibrin formation | 7 |
made using | 7 |
diagnostic markers | 7 |
intravascular coagulation | 7 |
hemolytic uremic | 7 |
turbidimetric assay | 7 |
thymidine incorporation | 7 |
detected using | 7 |
within evs | 7 |
significantly associated | 7 |
dose heparin | 7 |
equivalence group | 7 |
high mortality | 7 |
fatality rate | 7 |
control cells | 7 |
ko mice | 7 |
evs based | 7 |
protein electrophoresis | 7 |
protein bound | 7 |
supportive care | 7 |
sample preparation | 7 |
pathways involved | 7 |
control groups | 7 |
adhesion molecule | 7 |
production steps | 7 |
flow rate | 7 |
time pcr | 7 |
computed tomography | 7 |
accessibility matrix | 7 |
proteins associated | 7 |
restriction enzyme | 7 |
vesicle size | 7 |
health emergency | 7 |
ingenuity pathway | 7 |
recipient antibody | 7 |
sequential centrifugation | 7 |
boehringer mannheim | 7 |
ev core | 7 |
least two | 7 |
blood collected | 7 |
humoral immune | 7 |
combat casualties | 7 |
fibrin clot | 7 |
marker cd | 7 |
age years | 7 |
cell exosomes | 7 |
patients using | 7 |
mechanisms regulating | 7 |
assay using | 7 |
microvascular endothelial | 7 |
last decade | 7 |
protein aggregates | 7 |
calculated using | 7 |
force microscopy | 7 |
quantitative proteomics | 7 |
recent advances | 7 |
lmw heparin | 7 |
showed similar | 7 |
circulating dna | 7 |
tumour development | 7 |
recipient cell | 7 |
shape change | 7 |
incubation time | 7 |
resistant cell | 7 |
fibrinolytic therapy | 7 |
highly metastatic | 7 |
serum protein | 7 |
infected patients | 7 |
factor levels | 7 |
test analysis | 7 |
factor concentrates | 7 |
unfractionated heparin | 7 |
currently used | 7 |
therapeutic interventions | 7 |
dna analysis | 7 |
social distancing | 7 |
evs purified | 7 |
sequence motifs | 7 |
binding proteins | 7 |
exosome production | 7 |
small number | 7 |
iu kg | 7 |
two distinct | 7 |
weight proteins | 7 |
different proteins | 7 |
using transmission | 7 |
der lagerung | 7 |
communication via | 7 |
protein profiling | 7 |
senescent cells | 7 |
ev population | 7 |
high degree | 7 |
control resuscitation | 7 |
new biomarkers | 7 |
bypass surgery | 7 |
highly enriched | 7 |
protein analysis | 7 |
derived exosome | 7 |
urgent need | 7 |
mean values | 7 |
heart disease | 7 |
high doses | 7 |
will require | 7 |
preterm infants | 7 |
including extracellular | 7 |
small molecule | 7 |
polyethylene glycol | 7 |
current status | 7 |
anion exchange | 7 |
complex biological | 7 |
around nm | 7 |
therapeutic delivery | 7 |
clinical setting | 7 |
human induced | 7 |
gradient purification | 7 |
cells secrete | 7 |
prepared using | 7 |
acute coronary | 7 |
data capture | 7 |
additional studies | 7 |
inflammatory cells | 7 |
observation period | 7 |
adverse reactions | 7 |
reduction treatments | 7 |
different stages | 7 |
cigarette smoke | 7 |
drug development | 7 |
therapeutic targets | 7 |
intact evs | 7 |
significantly enhanced | 7 |
particle analysis | 7 |
live imaging | 7 |
exosomal micrornas | 6 |
novel ev | 6 |
levels increased | 6 |
treatment purposes | 6 |
based proteomics | 6 |
ml kg | 6 |
independent growth | 6 |
lung fibrosis | 6 |
enrolled patients | 6 |
antibody microarrays | 6 |
ev biology | 6 |
pediatric patients | 6 |
hopkins university | 6 |
tumour specific | 6 |
zikv infection | 6 |
foetal bovine | 6 |
fibrin degradation | 6 |
coding rna | 6 |
mitovesicle levels | 6 |
three patients | 6 |
der apherese | 6 |
induced changes | 6 |
product quality | 6 |
major risk | 6 |
disseminated intravascular | 6 |
higher sev | 6 |
antibody microarray | 6 |
similar size | 6 |
treated mice | 6 |
transmembrane proteins | 6 |
information regarding | 6 |
single evs | 6 |
clotting factor | 6 |
aerobic exercise | 6 |
cell lysate | 6 |
nanoscale flow | 6 |
plasma concentration | 6 |
granulation tissue | 6 |
well established | 6 |
position paper | 6 |
examined using | 6 |
cd counts | 6 |
antiviral agents | 6 |
microrna signatures | 6 |
bone formation | 6 |
cancer plasma | 6 |
new zealand | 6 |
thrombocyte count | 6 |
mouse pci | 6 |
resistant prostate | 6 |
allowed without | 6 |
severe bleedings | 6 |
reuse allowed | 6 |
inflammatory properties | 6 |
surface plasmon | 6 |
commons licence | 6 |
cell counts | 6 |
mrna targets | 6 |
mass index | 6 |
ev reference | 6 |
mechanisms underlying | 6 |
data provide | 6 |
sterile water | 6 |
ev sub | 6 |
highly desirable | 6 |
heparan sulphate | 6 |
expressed cd | 6 |
associated dna | 6 |
weniger als | 6 |
microrna expression | 6 |
group compared | 6 |
plasma components | 6 |
well tolerated | 6 |
multiple studies | 6 |
normal platelet | 6 |
human patients | 6 |
also show | 6 |
analysis demonstrated | 6 |
targeted therapy | 6 |
falciparum malaria | 6 |
disease diagnosis | 6 |
postcapillary venules | 6 |
local ethics | 6 |
will determine | 6 |
cerebral ischemia | 6 |
fluid stem | 6 |
specific marker | 6 |
several days | 6 |
matched control | 6 |
human mesenchymal | 6 |
extracellular space | 6 |
mit dem | 6 |
early disease | 6 |
intramural research | 6 |
new evidence | 6 |
high amounts | 6 |
san diego | 6 |
cord mesenchymal | 6 |
neural stem | 6 |
induced sputum | 6 |
tf viia | 6 |
regulatory authorities | 6 |
metastatic disease | 6 |
natural killer | 6 |
posted june | 6 |
pancreatic ductal | 6 |
lopinavir ritonavir | 6 |
optiprep density | 6 |
one cat | 6 |
active gbmsm | 6 |
ros production | 6 |
viral etiology | 6 |
hippocampal neurogenesis | 6 |
direct contact | 6 |
mustard gas | 6 |
rna analysis | 6 |
blood vessels | 6 |
isolated exosomes | 6 |
diagnostic efficacy | 6 |
brain derived | 6 |
sinai medical | 6 |
aged animals | 6 |
also identified | 6 |
electronic data | 6 |
proteolytic activity | 6 |
plasma exosomes | 6 |
hospital stay | 6 |
human platelets | 6 |
circulating mirna | 6 |
undergoing elective | 6 |
specific igg | 6 |
starting plasma | 6 |
oxygen saturation | 6 |
late endosomes | 6 |
decreased levels | 6 |
also shown | 6 |
large animal | 6 |
light scatter | 6 |
oxygen species | 6 |
will also | 6 |
clinical status | 6 |
tested using | 6 |
high resolution | 6 |
total particle | 6 |
one hour | 6 |
interferometric reflectance | 6 |
total plasma | 6 |
large number | 6 |
evidence suggests | 6 |
still unknown | 6 |
acquired pneumonia | 6 |
health science | 6 |
recombinant factor | 6 |
dendritic spines | 6 |
asthma patients | 6 |
complement cascade | 6 |
side scatter | 6 |
tissue biopsy | 6 |
male mice | 6 |
inflammatory processes | 6 |
exon ii | 6 |
delivery vehicle | 6 |
promote tumour | 6 |
significantly changed | 6 |
protein fractions | 6 |
mice models | 6 |
der gewinnung | 6 |
also known | 6 |
recent developments | 6 |
treating covid | 6 |
possible role | 6 |
specific patterns | 6 |
marrow derived | 6 |
version posted | 6 |
investigational covid | 6 |
fibrin complexes | 6 |
oral application | 6 |
plasma pool | 6 |
zika virus | 6 |
specific rna | 6 |
significantly correlated | 6 |
blood bank | 6 |
donor antibody | 6 |
resting platelets | 6 |
traditional drugs | 6 |
delivery vehicles | 6 |
human cancer | 6 |
previous study | 6 |
pl im | 6 |
arg gin | 6 |
blood volume | 6 |
dimer levels | 6 |
regression analysis | 6 |
patient outcomes | 6 |
rna library | 6 |
shaped morphology | 6 |
acid minus | 6 |
ev separation | 6 |
thrombotic microangiopathy | 6 |
exudate may | 6 |
mit einem | 6 |
specific cargo | 6 |
nanoflow cytometry | 6 |
colon cancer | 6 |
sexually active | 6 |
human islets | 6 |
also performed | 6 |
ciliary evs | 6 |
late stage | 6 |
citrated blood | 6 |
ffp transfusion | 6 |
leading causes | 6 |
hepfn ko | 6 |
therapeutic tools | 6 |
derived products | 6 |
mm caprylate | 6 |
average size | 6 |
melanocytic evs | 6 |
received funding | 6 |
protein microarrays | 6 |
protein recovery | 6 |
durch eine | 6 |
products using | 6 |
cells grown | 6 |
markedly increased | 6 |
glial cells | 6 |
three methods | 6 |
day precision | 6 |
mean fluorescence | 6 |
exoquick ultra | 6 |
stent implantation | 6 |
positive predictive | 6 |
ohsv resistant | 6 |
evaluated using | 6 |
cytometric analysis | 6 |
white blood | 6 |
without permission | 6 |
plasma mir | 6 |
baseline values | 6 |
cell biology | 6 |
von blutkomponenten | 6 |
capture evs | 6 |
db db | 6 |
donation programme | 6 |
lupus anticoagulants | 6 |
virus neutralization | 6 |
heparin treatment | 6 |
conditions used | 6 |
using cell | 6 |
fluorescent protein | 6 |
aptt reagent | 6 |
validated using | 6 |
stellate cells | 6 |
plaque assay | 6 |
adenosine diphosphate | 6 |
first study | 6 |
patients will | 6 |
lung infiltrates | 6 |
neurological diseases | 6 |
enveloped virus | 6 |
manufacturing steps | 6 |
induced acute | 6 |
significantly less | 6 |
low responders | 6 |
potential therapy | 6 |
endogenous dnase | 6 |
controlled conditions | 6 |
last months | 6 |
droplet based | 6 |
evs reduced | 6 |
und oder | 6 |
experimental conditions | 6 |
fluorescent labelling | 6 |
ionized calcium | 6 |
mononuclear cells | 6 |
pulmonary fibrosis | 6 |
augmentation therapy | 6 |
ev administration | 6 |
spectrometry analysis | 6 |
provide evidence | 6 |
cell media | 6 |
effective therapy | 6 |
late phase | 6 |
toxic proteins | 6 |
extremely high | 6 |
plasma containing | 6 |
pulmonary arterial | 6 |
molecule array | 6 |
cardiac function | 6 |
production process | 6 |
large plasma | 6 |
cystic fibrosis | 6 |
plasma study | 6 |
antithrombin agents | 6 |
decreased expression | 6 |
serum therapy | 6 |
profiling revealed | 6 |
cell marker | 6 |
analysis method | 6 |
remains unclear | 6 |
donation center | 6 |
biliary strictures | 6 |
derived mscs | 6 |
scientific research | 6 |
six months | 6 |
clinical utility | 6 |
ev fractions | 6 |
different time | 6 |
safety update | 6 |
antivenom production | 6 |
target genes | 6 |
several studies | 6 |
may help | 6 |
ev manufacturing | 6 |
reporter cells | 6 |
acinetobacter baumannii | 6 |
resistant cells | 6 |
cell cycles | 6 |
high titers | 6 |
blood level | 6 |
pathogen interactions | 6 |
mtbi patients | 6 |
integrated knowledge | 6 |
reported cases | 6 |
aged rats | 6 |
neck cancer | 6 |
major cause | 6 |
medium using | 6 |
statistical analysis | 6 |
inflammatory diseases | 6 |
rat model | 6 |
plasma obtained | 6 |
three groups | 6 |
factor deficiencies | 6 |
chronic stress | 6 |
situ hybridization | 6 |
specific treatment | 6 |
plasma volume | 6 |
divalent cations | 6 |
pathophysiological processes | 6 |
wird die | 6 |
specific protein | 6 |
low levels | 6 |
purified using | 6 |
developing world | 6 |
chromogenic substrate | 6 |
laboratory test | 6 |
epithelial shedding | 6 |
high potential | 6 |
human seminal | 6 |
extra centrosomes | 6 |
reverse transcription | 6 |
among others | 6 |
brain cells | 6 |
sec fractions | 6 |
pl aggregation | 6 |
ph incubation | 6 |
derived mesenchymal | 6 |
mediate intercellular | 6 |
pca patients | 6 |
cell count | 6 |
release extracellular | 6 |
study reported | 6 |
mediators may | 6 |
pandemic influenza | 6 |
cingulate cortex | 6 |
study shows | 6 |
cell myeloma | 6 |
producing cells | 6 |
virus infections | 6 |
cancer types | 6 |
takes place | 6 |
human convalescent | 6 |
two methods | 6 |
mucosal exudation | 6 |
vesicles derived | 6 |
progenitor cells | 6 |
yr cvd | 6 |
isolation kit | 6 |
underlying mechanisms | 6 |
cells cultured | 6 |
one another | 6 |
high affinity | 6 |
migration ability | 6 |
thromboembolic disease | 6 |
donor population | 6 |
disease models | 6 |
plasma cfdna | 6 |
tissue regeneration | 6 |
zu einer | 6 |
heparin induced | 6 |
white cells | 6 |
infectious agent | 6 |
gp iib | 6 |
treatment group | 6 |
treatment may | 6 |
anterior cingulate | 6 |
allergic reactions | 6 |
microvascular permeability | 6 |
patients treatment | 6 |
driven opc | 6 |
melanomic evs | 6 |
including cancer | 6 |
many studies | 6 |
isolate exosomes | 6 |
th cells | 6 |
drug abuse | 6 |
dna fragments | 6 |
acute renal | 6 |
released evs | 6 |
antiviral strategies | 6 |
ev subpopulation | 6 |
pc cells | 6 |
concentration ratio | 6 |
per day | 6 |
mrna levels | 6 |
new drug | 6 |
journal club | 6 |
ev precipitation | 6 |
ml plasma | 6 |
take place | 6 |
flow field | 6 |
increased proliferation | 6 |
calibration curve | 6 |
ev heterogeneity | 6 |
tau propagation | 6 |
tnbc cells | 6 |
taking advantage | 6 |
human pancreas | 6 |
higher expression | 6 |
fibrin monomers | 6 |
filopodia formation | 6 |
transfusion transmitted | 6 |
circulating microrna | 6 |
melanoma cells | 6 |
inactivation treatments | 6 |
cell signalling | 6 |
depleted fbs | 6 |
significant risk | 6 |
microfluidic platform | 6 |
type plasminogen | 6 |
feline coronavirus | 6 |
san francisco | 6 |
patients infected | 6 |
dna cargo | 6 |
related genes | 6 |
proteomic analyses | 6 |
one condition | 6 |
log fc | 6 |
one essential | 6 |
paca cell | 6 |
screening questions | 6 |
mouse islets | 6 |
rna content | 6 |
expression pattern | 6 |
targeted delivery | 6 |
aus der | 6 |
digital droplet | 6 |
calu evs | 6 |
positively associated | 6 |
collection tubes | 6 |
high concentration | 6 |
affinity column | 6 |
boyden chamber | 6 |
national science | 6 |
mit einer | 6 |
case fatality | 6 |
einsatz von | 6 |
transgenic mouse | 6 |
vwf release | 6 |
identified proteins | 6 |
related proteins | 6 |
ucm blood | 6 |
national research | 6 |
coronary syndromes | 6 |
bag system | 6 |
successfully isolated | 5 |
blood platelets | 5 |
interviews will | 5 |
immunogold labelling | 5 |
will enhance | 5 |
antiasthma drugs | 5 |
recruitment strategy | 5 |
inflammatory effect | 5 |
different populations | 5 |
metastasis suppressor | 5 |
den richtlinien | 5 |
particle count | 5 |
eight patients | 5 |
south korea | 5 |
using plasma | 5 |
specific surface | 5 |
shh signalling | 5 |
kras mutations | 5 |
kg min | 5 |
vwf levels | 5 |
ev composition | 5 |
surface charge | 5 |
genes involved | 5 |
urokinase receptor | 5 |
vivo biodistribution | 5 |
ev fingerprinting | 5 |
collagen sponge | 5 |
vitro plasma | 5 |
blood operators | 5 |
may prevent | 5 |
endothelial damage | 5 |
one hand | 5 |
high gain | 5 |
canonical pathways | 5 |
nuclear transfer | 5 |
urinary ev | 5 |
thereby increasing | 5 |
showed higher | 5 |
much higher | 5 |
pcr amplification | 5 |
collagen type | 5 |
fractionation industry | 5 |
potential diagnostic | 5 |
aml patients | 5 |
cell neoplasms | 5 |
specific antigen | 5 |
platelet transfusions | 5 |
abundant protein | 5 |
age ys | 5 |
ev number | 5 |
isolation techniques | 5 |
serum amyloid | 5 |
isolating evs | 5 |
showed increased | 5 |
positive sevs | 5 |
virus antibodies | 5 |
significant adverse | 5 |
absorption barrier | 5 |
therapeutic response | 5 |
altered expression | 5 |
exercised mice | 5 |
sickle cell | 5 |
anticoagulant activity | 5 |
acid metabolism | 5 |
several different | 5 |
msc derived | 5 |
rna isolation | 5 |
tumour dna | 5 |
producer cells | 5 |
old therapeutic | 5 |
via differential | 5 |
viral kill | 5 |
using ultrafiltration | 5 |
purification protocols | 5 |
cell transplantation | 5 |
derived cells | 5 |
heat shock | 5 |
hyperimmune plasma | 5 |
enriched proteins | 5 |
prognostic value | 5 |
stage renal | 5 |
american heart | 5 |
used convalescent | 5 |
small non | 5 |
albumin levels | 5 |
enriched evs | 5 |
factors may | 5 |
epithelial barriers | 5 |
copies per | 5 |
cd aptamer | 5 |
buenos aires | 5 |
cultured human | 5 |
significantly greater | 5 |
airway diseases | 5 |
myeloid cells | 5 |
deep venous | 5 |
immunofluorescence staining | 5 |
important roles | 5 |
high prevalence | 5 |
gene transcription | 5 |
neuroprotective properties | 5 |
rich source | 5 |
quantitative proteomic | 5 |
ischaemia reperfusion | 5 |
bleeding disorder | 5 |
using mouse | 5 |
cells contain | 5 |
lining cells | 5 |
evs captured | 5 |
therapy response | 5 |
nanotracking analysis | 5 |
personalized medicine | 5 |
blood regulators | 5 |
donor eligibility | 5 |
total calcium | 5 |
ethanol precipitate | 5 |
host cell | 5 |
several months | 5 |
primary cell | 5 |
hepatic stellate | 5 |
high yield | 5 |
specific exosomes | 5 |
uev proteome | 5 |
also increased | 5 |
previously identified | 5 |
pretreatment titre | 5 |
empirical treatment | 5 |
ad evs | 5 |
tissue homoeostasis | 5 |
bioinformatic analysis | 5 |
beta integrin | 5 |
described previously | 5 |
human protein | 5 |
based photochemical | 5 |
coronary risk | 5 |
cellular pathways | 5 |
various cell | 5 |
current pandemic | 5 |
model system | 5 |
mitochondrial origin | 5 |
family history | 5 |
sd treatment | 5 |
transform infrared | 5 |
immunoglobulin products | 5 |
sample volume | 5 |
biodistribution studies | 5 |
local advisory | 5 |
cultured endothelial | 5 |
immune modulatory | 5 |
kommt es | 5 |
protein mass | 5 |
translational research | 5 |
implementing revised | 5 |
activated factor | 5 |
neck squamous | 5 |
clinical manifestation | 5 |
control measures | 5 |
findings support | 5 |
lipid membrane | 5 |
stim plus | 5 |
donation testing | 5 |
systemic inflammation | 5 |
primary neurons | 5 |
dependent inhibition | 5 |
des spenders | 5 |
wide variety | 5 |
metastatic lung | 5 |
blood brain | 5 |
gfp evs | 5 |
health problem | 5 |
single vesicle | 5 |
therapeutic option | 5 |
isev workshops | 5 |
lipoprotein particles | 5 |
infected individuals | 5 |
old male | 5 |
durch einen | 5 |
end stage | 5 |
prolonged aptt | 5 |
treatment options | 5 |
flow conditions | 5 |
serine proteinase | 5 |
quantitative pcr | 5 |
physiological functions | 5 |
database search | 5 |
human cd | 5 |
research institute | 5 |
human bone | 5 |
titer centers | 5 |
us southwest | 5 |
ms patients | 5 |
die transfusion | 5 |
ev functionality | 5 |
alveolar type | 5 |
developing new | 5 |
using confocal | 5 |
real time | 5 |
using rt | 5 |
ev function | 5 |
access program | 5 |
diseases may | 5 |
therefore conclude | 5 |
mucosal permeability | 5 |
type diabetic | 5 |
metabolic stress | 5 |
human cancers | 5 |
virus reduction | 5 |
extracellular rna | 5 |
therapeutic tool | 5 |
adult respiratory | 5 |
evs collected | 5 |
ii iii | 5 |
purification steps | 5 |
evs associated | 5 |
higher protein | 5 |
hemorrhagic fever | 5 |
intravenous immunoglobulins | 5 |
iodixanol gradient | 5 |
clinical benefit | 5 |
chronic cd | 5 |
samples using | 5 |
spectral bands | 5 |
bis zu | 5 |
ductal adenocarcinoma | 5 |
validation experiments | 5 |
small volumes | 5 |
may need | 5 |
blast crisis | 5 |
first days | 5 |
thomas jefferson | 5 |
small particles | 5 |